What Can Biomarkers Tell Us? Modern Tools to Assist Navigating Prognosis, Monitoring, and Therapeutic Decision-Making in the Long-Term Management of Multiple Sclerosis

June 1, 2022

Overview

This satellite symposium to be held in conjunction with the 2022 Consortium of Multiple Sclerosis (MS) Centers (CMSC) Annual Meeting is designed to elucidate the perspectives of noted experts on existing and rising indicators of MS prognosis and/or disease activity (e.g., serum biomarkers, lesion topography, etc.). During the program, invited faculty will advocate for their preferred biomarkers and/or clinical indicators and why they may represent the future of successful disease management. By gaining understanding of exactly how and why these factors should (or should not) be considered, clinicians may better navigate and optimize available tools and strategies for their patients.

Target Audience

The target audience for this activity includes MS specialists, general neurologists, nurse practitioners, physician assistants, registered nurses, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Assess the relative roles of existing predictors/indicators of disease progression to guide the prioritization of these factors in proactive assessment of patient changes.
  • Appraise the utility of clinical and radiologic assessments of disease progression to select the most sensitive and clinically appropriate monitoring tools that will not disrupt current workflow.
  • Analyze emerging research on “induction” vs. “escalation” and disease-modifying therapy (DMT) switching strategies as well the influence of clinical/radiologic disease indicators to improve therapeutic decision-making and maximize patient outcome.
  • Evaluate published research and expert experience with the use of individual DMTs for patients in different disease states (e.g., active/inactive, relapsing/progressive) to help determine the optimal therapeutic approach for individual patients.
Course summary
Course opens: 
03/31/2022
Course expires: 
03/25/2023
Event starts: 
06/01/2022 - 4:00pm EDT
Event ends: 
06/01/2022 - 5:30pm EDT
Cost:
$0.00
Rating: 
0

INTRODUCTION

4:05 - 4:10PM • DR OH

PART 1: The Active Role of Prognostics – How and Which Factors Effect Initial Clinical Decision Making

4:11 - 4:41PM

  • FACULTY STANCE AND SUPPORTING DATA: DR SHIN AND DR OH

Drs Shin and Oh will advocate for one or more of the following as the most promising/valuable in gauging the trajectory of a patients disease course:
Brain volume
Clinical Features (e.g., Initial relapse type, relapse frequency/recovery)
Glial fibrillary protein (GFAP)
MRI elements (e.g., lesion number, location)
Neurofilament light chain (NfL)
Optical Coherence Tomography (OCT)/Retinal nerve fiber layer (RNFL)
Paramagnetic rim lesions
  • MODERATED FACULTY DISCUSSION ON APPLICATIONS AND LIMITATIONS IN PATIENT CARE

PART 2: Follow the Signs – Using Clinical and Biological Cues to Monitor Disease and Inform Therapeutic Change

4:42 - 5:12PM

  • FACULTY STANCE AND SUPPORTING DATA: DRS GRAVES AND BAR-OR

Drs Graves and Bar-Or will advocate for one or more of the following as the most  promising/valuable in monitoring for disease progression and making therapeutic changes:

Brain volume 
Central vein sign
Cognitive measures
Digital tools
Disability scales (e.g., T25FW, SDMT)
Conventional MRI elements (e.g., lesion number, location)
GFAP
NfL
OCT/RNFL
Paramagnetic rim lesions
  •  MODERATED FACULTY DISCUSSION ON APPLICATIONS AND LIMITATIONS IN PATIENT CARE

FULL PANEL DISCUSSION/DEBATE

5:12 - 5:20PM

Q&A

5:20 - 5:30PM

This symposium is neither sponsored nor endorsed by the CMSC.

   Jiwon Oh, MD, PhD, FRCPC (Moderator and Chair)
   Medical Director, Barlo MS Program
   St. Michael’s Hospital
   Scientist, Keenan Research Centre
   Li Ka Shing Knowledge Institute
   Associate Professor of Medicine
   University of Toronto
   Toronto, Ontario, Canada

 

   Amit Bar-Or, MD, FRCPC
   Director, Center for Neuroinflammation and Neurotherapeutics
   Chief, Multiple Sclerosis Division
   Melissa and Paul Anderson President’s Distinguished Professor
   Perelman Center for Advanced Medicine
   Penn Medicine
   Philadelphia, PA

 

   Jennifer Graves MD, PhD
   Neurologist
   Associate Professor of Neurosciences
   UC San Diego Health
   San Diego, California



 

   Robert Shin, MD
   Director, Georgetown Multiple Sclerosis and Neuroimmunology Center
   Professor, Department of Neurology
   Georgetown University Medical Center
   Washington, DC

This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

        

Accreditation Statement

In support of improving patient care, MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Physician Credit

MER designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources designates this live activity for a maximum of 1.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Disclosure of Conflict of Interest

Disclosures

MER requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All relevant financial relationships have been mitigated by MER. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners’ and Managers’ Disclosure

MER planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Faculty Disclosures

Dr Oh reported the following financial relationships:

  • Consulting Fees: Alexion, Biogen, Bristol Myers Squibb, Novartis, Roche, Sanofi-Genzyme
  • Grants/Research Support: Biogen, EMD Serono, Roche

Dr Bar-Or reported the following financial relationships:

  • Grants/Research Support: University of Pennsylvania, Biogen Idec, Genentech/Roche, Merck/EMD Serono; Novartis
  • Consulting Fees: Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Genentech/Roche, Sanofi-Genzyme

Dr Graves reported the following financial relationships:

  • Consulting Fees: Genentech
  • Fees for Non-CE Services: BMS, Alexion
  • Grants/Research Support: Biogen, EMD Serono
  • Clinical Steering Committee: Novartis

Dr Shin reported the following financial relationships:

  • Consulting Fees: Celgene, Biogen, Genzyme, Novartis
  • Speakers' Bureau: Alexion, EMD Serono, Genentech, Mallinckrodt

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by an educational grant from Genentech, A Member of the Roche Group.

Price

Cost:
$0.00
Please login or register to take this course.